Initiation of coverage report on Kadimastem by global research firm Frost & Sullivan: sherzlJun 13, 20181 min readUpdated: Jan 7, 2019 Report in English and a Hebrew summaryhttps://maya.tase.co.il/reports/details/1167249/2/0https://maya.tase.co.il/reports/details/1167247/2/0
Kadimastem and NLS Pharmaceutics Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies
Comments